Kidney Transplant Rejection: Symptoms, Types, and Treatment

Kidney transplant rejection occurs when the recipient's immune system recognizes the donated kidney as foreign and mounts an attack against it. There are three distinct types — hyperacute, acute, and chronic — each with different timelines, warning signs, and treatments. The critical fact every transplant patient must understand is this: most rejection episodes produce no noticeable symptoms at all, which is why consistent laboratory monitoring and follow-up appointments are as important as the surgery itself.

As a transplant surgeon with more than 20 years of experience and over 2,000 procedures performed at Centro Médico González in Mexicali, I've guided hundreds of patients through the uncertainty that follows transplantation. This guide covers everything you need to know about recognizing rejection, what your care team does when it happens, and how modern immunosuppression has made successful long-term outcomes the norm rather than the exception.

Understanding Why Rejection Happens

The Immune System's Role

The human immune system is extraordinarily good at distinguishing "self" from "non-self." When a kidney is transplanted — even one that is well-matched to the recipient — the recipient's T lymphocytes (T cells) and B lymphocytes (B cells) can identify the donor organ's surface proteins as foreign antigens. Without immunosuppressive therapy, the immune response would destroy the transplanted kidney within days.

Why Matching Reduces But Does Not Eliminate Risk

Histocompatibility testing (HLA typing) and cross-matching before transplant significantly reduce rejection risk. However, even a six-antigen match — the best possible outcome between non-identical donors — does not produce zero rejection risk. The immune system's sensitivity is such that minor antigen differences can still trigger a response over months or years.

Risk Factors That Increase Rejection Probability

Several factors raise a recipient's rejection risk above the population baseline:

Poor medication adherence — missing even a few doses of tacrolimus or mycophenolate mofetil dramatically elevates risk
Infections — particularly viral infections that activate the immune system broadly
High panel reactive antibody (PRA) levels before transplant, indicating a sensitized immune system
Prior transplant failure — previous transplants leave lasting immune memory
Poorly controlled blood pressure or diabetes — both stress the transplanted kidney and may accelerate chronic changes

The 3 Types of Kidney Transplant Rejection

Type 1: Hyperacute Rejection

Hyperacute rejection occurs within minutes to hours of the surgical connection between recipient and donated kidney. It is caused by pre-formed antibodies in the recipient's bloodstream — antibodies that were already present before transplant and immediately attack the donor organ's blood vessels.

What Happens During Hyperacute Rejection

When blood flow is restored to the donated kidney, the pre-formed antibodies bind to endothelial cells lining the kidney's blood vessels. This triggers complement activation, platelet aggregation, and rapid thrombosis (clotting) within the glomerular capillaries. The kidney turns from healthy pink to mottled blue-gray within minutes. Urine output fails to begin.

How Rare Is Hyperacute Rejection Today?

Hyperacute rejection is now extremely rare — fewer than 1% of transplants in centers with rigorous pre-transplant testing. Modern cross-matching techniques, including flow cytometry cross-match and the complement-dependent cytotoxicity (CDC) cross-match, detect incompatible pre-formed antibodies before surgery. ABO blood group compatibility testing eliminates another major cause. If the cross-match is positive, transplantation does not proceed.

Treatment of Hyperacute Rejection

Unfortunately, hyperacute rejection cannot be reversed. The transplanted kidney must be surgically removed (graft nephrectomy) immediately. The patient returns to dialysis while evaluation for re-listing begins. This is why pre-transplant screening is so thorough and why a positive cross-match is an absolute contraindication to transplant.

Type 2: Acute Rejection

Acute rejection is the most commonly discussed type. It typically occurs within the first days to 12 months after transplantation, with the highest risk in the first three months. There are two mechanistic subtypes that require different treatment approaches.

Acute T-Cell Mediated Rejection (TCMR)

In TCMR, T lymphocytes infiltrate the kidney tissue itself — specifically the tubules (tubulitis) and the interstitial space (interstitial nephritis). In severe cases, they also infiltrate arterial walls (endarteritis). The Banff classification system grades TCMR from IA (mild) to III (severe) based on the degree of infiltration and vascular involvement.

TCMR is the type most responsive to treatment and, when caught early, rarely leads to permanent graft loss.

Acute Antibody-Mediated Rejection (ABMR)

ABMR occurs when B cells produce donor-specific antibodies (DSA) — antibodies targeted specifically at HLA antigens expressed by the donated kidney. These antibodies cause injury to the peritubular capillaries (peritubular capillaritis) and glomeruli (glomerulitis). ABMR is detected through DSA blood testing and biopsy findings, including C4d staining of the peritubular capillaries.

ABMR is generally more difficult to treat than TCMR and carries a higher risk of progression to chronic rejection if not controlled promptly.

Symptoms of Acute Rejection

It is essential to repeat: many episodes of acute rejection produce no symptoms. This is why laboratory monitoring — creatinine every one to two weeks in the first months, then monthly — is non-negotiable.

When symptoms do occur, they may include:

Fever above 38°C (100.4°F), sometimes with chills
Pain or tenderness at the transplant site (typically the lower abdomen, left or right iliac fossa)
Decreased urine output despite normal fluid intake
Sudden weight gain of more than 1–2 kg within 24–48 hours (fluid retention)
Swelling in the ankles and legs
Elevated blood pressure that is difficult to control with usual medications
Fatigue and general malaise

If you experience any combination of these symptoms, contact your transplant team immediately — do not wait for a scheduled appointment.

Type 3: Chronic Rejection (Chronic Allograft Nephropathy)

Chronic rejection — more precisely termed chronic allograft nephropathy or interstitial fibrosis and tubular atrophy (IF/TA) in current Banff nomenclature — develops months to years after transplant. It is the leading cause of late kidney graft loss.

How Chronic Rejection Differs

Unlike acute rejection, chronic rejection is a slow, progressive process. The kidney loses function gradually, often over months or years, without dramatic symptoms. Patients may notice only a gradual rise in creatinine, worsening blood pressure control, or increasing protein in the urine (proteinuria) at routine follow-up.

Mechanisms Behind Chronic Rejection

Chronic rejection has both immunological and non-immunological causes:

Cumulative immune injury — subclinical acute rejection episodes that were never symptomatic but caused incremental damage over time
Calcineurin inhibitor nephrotoxicity — tacrolimus and cyclosporine, the cornerstones of immunosuppression, can themselves cause chronic kidney injury at higher levels
Recurrent disease — some conditions that caused the original kidney failure (such as IgA nephropathy or focal segmental glomerulosclerosis) can recur in the transplanted kidney
Hypertension and diabetes — both accelerate vascular and glomerular scarring in the graft
Donor-specific antibodies (DSA) developing late, often related to medication non-adherence

Why Chronic Rejection Is Difficult to Treat

There is no definitive treatment that reverses established IF/TA. Management focuses on slowing progression: optimizing immunosuppression, controlling blood pressure (target <130/80 mmHg), managing blood glucose (HbA1c <7%), and treating any identified DSA. In some cases, switching from tacrolimus to an mTOR inhibitor (sirolimus or everolimus) may reduce nephrotoxicity while preserving immunosuppression.

How Rejection Is Diagnosed

Creatinine and GFR Monitoring

Serum creatinine and estimated glomerular filtration rate (eGFR) are the primary screening tools. A rise in creatinine of 20–25% above baseline should prompt urgent evaluation. In the immediate post-transplant period, creatinine is checked daily while the patient is hospitalized, then every 1–2 weeks for the first 3 months.

Donor-Specific Antibody (DSA) Testing

DSA testing detects antibodies specifically targeting the donor's HLA antigens. The presence of de novo (newly formed) DSA — particularly class II DSA — is a strong predictor of ABMR and graft loss. Many programs now routinely screen for DSA at 1, 3, 6, and 12 months after transplant, then annually.

Kidney Biopsy — The Gold Standard

When creatinine rises or DSA is detected, a percutaneous kidney biopsy provides definitive diagnosis. Using ultrasound guidance, a needle obtains two cores of kidney tissue, which are then analyzed by pathologists using the internationally standardized Banff classification criteria. The biopsy distinguishes between TCMR, ABMR, calcineurin inhibitor toxicity, recurrent disease, and other causes of graft dysfunction.

At our center in Mexicali, kidney biopsies are performed as outpatient procedures under local anesthesia with ultrasound guidance, with results typically available within 24–48 hours.

Protocol Biopsies

Some transplant programs perform scheduled "protocol biopsies" at 1, 3, and 12 months after transplant — regardless of whether creatinine has risen — to detect subclinical rejection early. This practice remains debated, but evidence suggests that treating subclinical TCMR improves long-term graft survival.

Treatment of Kidney Transplant Rejection

Treating Acute T-Cell Mediated Rejection (TCMR)

For mild to moderate TCMR (Banff IA and IB), the standard treatment is high-dose intravenous methylprednisolone — typically 500 mg daily for 3 days. This pulse of corticosteroids suppresses the T-cell infiltration and reverses dysfunction in the majority of cases.

For vascular TCMR (Banff IIA–III), lymphocyte-depleting therapy with anti-thymocyte globulin (ATG) is added. ATG eliminates circulating T cells more comprehensively than steroids alone. The immunosuppressive maintenance regimen is also reviewed and optimized — often increasing tacrolimus target levels or switching antiproliferative agents.

Treating Acute Antibody-Mediated Rejection (ABMR)

ABMR treatment aims to remove the existing donor-specific antibodies and suppress further antibody production:

Plasmapheresis (plasma exchange) — removes circulating DSA from the bloodstream. Typically performed every other day for 5–7 sessions.
Intravenous immunoglobulin (IVIG) — administered after plasmapheresis; helps neutralize remaining antibodies and modulates B-cell function.
Rituximab — a monoclonal antibody targeting CD20 on B cells, reducing further DSA production. One or two doses are given intravenously.
Bortezomib — a proteasome inhibitor that targets plasma cells (long-lived antibody-producing cells); used in cases of severe or refractory ABMR.
Eculizumab — a complement inhibitor that blocks C5 and may limit endothelial damage in severe ABMR; less commonly available due to cost.

The response rate to combination ABMR therapy ranges from 40–60%, with outcomes highly dependent on the degree of baseline kidney damage and the speed of diagnosis.

The Role of Tacrolimus

Tacrolimus remains the cornerstone of immunosuppressive therapy and the primary tool for rejection prevention. Clinical research has clearly demonstrated that tacrolimus produces significantly lower acute rejection rates than cyclosporine — approximately 14% vs. 24% in comparative studies. As Dr. César Eduardo González Muñoz explains to his patients: *"Tacrolimus levels in the blood must be maintained within a narrow therapeutic window — too low and rejection risk rises sharply; too high and kidney toxicity becomes a concern. This balance is why your blood draws are never optional."*

Tacrolimus is typically combined with mycophenolate mofetil (MMF) and low-dose prednisone in a triple-therapy regimen. Some protocols allow prednisone withdrawal after 3–6 months in low-risk patients.

Rejection Rates: What the Data Shows

Understanding real-world rejection rates helps patients calibrate their expectations. In a Mexican hospital study spanning 13 years of transplant experience, graft rejection occurred in approximately 18.8% of cases — a figure consistent with international experience in centers with varied recipient populations and follow-up protocols. Leading international programs report acute rejection rates of 10–20% at one year.

The most significant predictor of lower rejection rates across all centers is medication adherence. Patients who never miss a dose of their immunosuppressive regimen have rejection rates dramatically lower than those with even occasional missed doses. This is the single most controllable variable in your post-transplant outcome.

Prevention: Your Best Defense Against Rejection

Medication Adherence Is Non-Negotiable

Immunosuppressive medications must be taken every day, at the same time each day, for life. Tacrolimus has a short half-life; missing even one dose can cause blood levels to fall below therapeutic range within hours. Establish a routine: take medications with a small meal at the same time each morning and evening, set phone alarms, and never rely on memory alone.

Regular Laboratory Monitoring

Follow your transplant team's laboratory schedule exactly. In the first year, this typically means:

Weeks 1–4: creatinine, tacrolimus levels, complete blood count weekly
Months 1–3: labs every 2 weeks
Months 3–12: labs monthly
After year 1: labs every 2–3 months (or more frequently based on individual risk)

Do not skip labs because you feel well. Most rejection episodes are detected by rising creatinine before any symptoms appear.

Blood Pressure and Diabetes Control

Target blood pressure below 130/80 mmHg. If you have diabetes, maintain HbA1c below 7%. Both conditions directly damage transplanted kidneys and accelerate chronic rejection.

Avoiding Infections

Immunosuppression reduces your ability to fight infection. Avoid crowded settings during flu season, stay current on non-live vaccines (annual influenza, pneumococcal, hepatitis B), and contact your transplant team at the first sign of fever or illness — some infections trigger immune activation that can precipitate rejection.

Living With a Transplanted Kidney: Long-Term Outlook

Graft Survival Statistics

With modern immunosuppression and monitoring, one-year kidney graft survival rates exceed 95% at experienced centers. Five-year graft survival is approximately 80–85% for living donor transplants and 70–75% for deceased donor transplants. The goal of ongoing management is to push those long-term outcomes higher.

What Happens If the Kidney Fails

If the transplanted kidney eventually fails despite treatment, patients return to dialysis. Retransplantation is possible for many patients and remains the optimal long-term solution, though sensitization from prior transplants must be carefully evaluated.

Accessing Expert Transplant Care in Mexicali

For patients from the United States — particularly those in California, Arizona, and the broader Southwest — Mexicali offers unique advantages in follow-up care. Centro Médico González is located just 5 minutes from the Calexico, CA border crossing, making it straightforward to access Dr. González's post-transplant monitoring services without long-distance travel.

Dr. César Eduardo González Muñoz holds specialty board certification from the Consejo Mexicano de Cirugía General (Cédula 8274619, COFEPRIS 21020353A00412) and has performed more than 2,000 transplant and hepatobiliary procedures over a 20-year career. He collaborates with nephrologists, immunologists, and pathologists to provide the comprehensive monitoring that successful long-term transplant outcomes require.

Frequently Asked Questions About Kidney Transplant Rejection

What are the first signs of kidney transplant rejection? The first detectable sign is almost always a rise in serum creatinine — often before any physical symptoms appear. When symptoms do occur, they include fever above 38°C, tenderness at the transplant site in the lower abdomen, decreased urine output, sudden weight gain (fluid retention), leg swelling, and difficult-to-control blood pressure. Because most episodes are asymptomatic, regular lab monitoring is essential and non-optional.

How soon after a kidney transplant can rejection happen? Rejection can occur at any time after transplant. Hyperacute rejection happens within minutes to hours of the transplant surgery. Acute rejection most commonly occurs within the first 3–12 months, with the highest risk in the first 90 days. Chronic rejection develops gradually over months or years and is the primary cause of late graft loss.

Can kidney transplant rejection be reversed? Acute T-cell mediated rejection (TCMR) is reversed in the majority of cases with high-dose intravenous methylprednisolone and, if needed, anti-thymocyte globulin. Acute antibody-mediated rejection (ABMR) is more challenging, but combination therapy with plasmapheresis, IVIG, and rituximab achieves a response in 40–60% of cases. Established chronic rejection (IF/TA) cannot be reversed, though its progression can be slowed.

Is kidney transplant rejection painful? Not always. Most rejection episodes are painless and detected only through blood tests. When pain does occur, it typically presents as tenderness or pressure over the transplant site in the lower abdomen. Severe pain is unusual unless there is a concurrent surgical complication.

What happens to immunosuppressive medications during a rejection episode? During treatment for acute rejection, immunosuppression is intensified — not reduced. Pulse steroid doses are given, tacrolimus target levels are often increased, and additional agents may be added. After successful treatment, some programs may adjust the regimen back toward maintenance levels, while others maintain higher levels for a period of monitoring.

How does a kidney biopsy diagnose rejection? A percutaneous kidney biopsy uses ultrasound guidance to obtain small tissue cores from the transplanted kidney. These are analyzed by pathologists using the Banff classification system, which grades inflammation, tubulitis, arteritis, C4d staining (indicating antibody involvement), and fibrosis. The biopsy result directs specific treatment — TCMR and ABMR require different therapies, so biopsy is essential before escalating treatment.

What is the most important thing I can do to prevent rejection? Take your immunosuppressive medications exactly as prescribed, every day, at the same time of day, for life. Medication non-adherence is the single most common avoidable cause of acute rejection and graft loss. The second most important prevention strategy is attending all scheduled follow-up appointments and laboratory draws — even when you feel perfectly well.

Can rejection happen years after a successful kidney transplant? Yes. Chronic rejection typically develops years after transplant and can affect kidneys that have functioned well for 5, 10, or even 15+ years. De novo donor-specific antibodies (DSA) can develop at any point, often triggered by changes in immunosuppression, infections, or non-adherence. Annual monitoring of DSA and kidney function is recommended indefinitely.

Does tacrolimus prevent rejection better than older medications? Yes. Clinical research confirms that tacrolimus-based immunosuppression produces acute rejection rates of approximately 14%, compared to approximately 24% with cyclosporine-based regimens. Tacrolimus is now the first-line calcineurin inhibitor at virtually all transplant centers worldwide. The combination of tacrolimus, mycophenolate mofetil, and low-dose prednisone (triple therapy) represents the current standard of care.

What should I do if I think I'm rejecting? Contact your transplant team immediately — by phone, not by waiting for a scheduled appointment. Do not wait to see if symptoms resolve on their own. If you are unable to reach your transplant team and symptoms are severe, go to the nearest emergency department and tell them you are a kidney transplant recipient. Bring your medication list and transplant center contact information.

Schedule a Post-Transplant Consultation

Whether you received your transplant at another center and are seeking expert follow-up care closer to the US-Mexico border, or you are evaluating kidney transplantation for the first time, Dr. César Eduardo González Muñoz and his team at Centro Médico González welcome patients from across Mexico and the United States.

Our clinic is located at C. I 1701, entre Calle Zaragoza y Calle Vicente Guerrero, Mexicali, B.C. — a 5-minute drive from the Calexico, CA border crossing. You can reach us at +52-686-338-3848 to schedule an evaluation.

Early detection and aggressive treatment of rejection episodes are what separate a functioning transplant at year 10 from one lost at year 2. Don't wait for symptoms — let us monitor you proactively.

Contact & Clinic Location

Clinic Address: Plaza Zaragoza, Calle I #1701, between Zaragoza & Vicente Guerrero, Col. Nueva, 21100 Mexicali, B.C., México.

Phone: (686) 338-3848

Office Hours: Monday to Saturday: 9AM - 7PM

Request Consultation & Guidance

Complete the form below to contact our clinical coordinator directly.